NCT05741242 — Jaime Leandro Foundation for Therapeutic… neoantigen vaccine trial
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Registry record
| Registry ID | NCT05741242 ↗ |
|---|---|
| Lead sponsor | Jaime Leandro Foundation for Therapeutic Cancer Vaccines |
| Collaborators | — |
| Phase | Phase 1/2 |
| Status | Enrolling By Invitation |
| Indication | Cancer, Solid Tumor |
| Enrollment | 136 participants (target) |
| Start date | 2022-11-30 |
| Primary completion | 2027-01 (est.) |
| Last registry update | 15 Jan 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT05741242), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT05741242?
NCT05741242 (A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors) is registered on ClinicalTrials.gov as Phase 1/2, sponsored by Jaime Leandro Foundation for Therapeutic Cancer Vaccines.
Is NCT05741242 recruiting?
As of the 2026-01-15 registry update, NCT05741242 is listed as "Enrolling By Invitation". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT05741242?
The lead sponsor is Jaime Leandro Foundation for Therapeutic Cancer Vaccines.
What condition does NCT05741242 study?
The registered conditions are Cancer, Solid Tumor. Primary completion is listed as 2027-01 (estimated).
Are results available for NCT05741242?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT05741242.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.